Good Growth Capital
VC Fund
Charleston, United States
Good Growth Capital is a VC fund in Charleston focused on Health Care and Biotechnology. Good Growth Capital provides investors with exceptional returns through our ability to source, assess and invest in early-stage transformative science- and technology-based companies in life sciences, data sciences, and greentech/hard sciences.
- Total investments:
- 120
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Good Growth Capital invests in
Stages Good Growth Capital invests in
Countries Good Growth Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $505k–$9M
- Series A
- $4.2M–$20M
- Convertible Note
- $25k–$300k
Investment Focus
Industry
- Health Care 14 (12%)
- Biotechnology 11 (9%)
- Software 10 (8%)
- Information Technology 9 (8%)
- Medical Device 8 (7%)
Stage
- Seed 33 (28%)
- Series A 22 (18%)
- Convertible Note 16 (13%)
- Funding Round 8 (7%)
- Venture - Series Unknown 4 (3%)
Country
- United States 50 (42%)
- France 1 (1%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amy Salzhauer
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 10 | Find email | |
Carolyne LaSala
Partner and Managing Partner
|
Partner and Managing Partner | Total investments: 5 | Find email | |
DAVID MENDEZ
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
DAVID MENDEZ
Managing Partner
|
Managing Partner | Total investments: 34 | Find email | |
John Osborne
Managing Partner
|
Managing Partner | Total investments: 6 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ateios
|
Ateios is enabling a new generation of thin and flexible electronics with our ultra-thin, conformable, and customizable batteries. The company's current focus is zinc-oxide batteries, that achieve 2-5x higher energy density compared to coin cells. Ateios’ novel manufacturing process allows customizable batteries that can be shaped around theneeds of the product.The company was founded in 2018. | $7.3M / Series A / Mar 23, 2026 | |
Avisi Technologies
|
Avisi Technologies develops ophthalmic medical devices using nanotechnology to address vision loss associated with glaucoma and related eye conditions. The company designs implantable solutions such as VisiPlate, an aqueous shunt that regulates intraocular fluid through microchannel structures to help manage eye pressure. Its work combinesmaterials science and ophthalmology to create minimally invasive devices intended for long-term function within the eye. | $10.8M / Series A / Feb 25, 2026 | |
Dalan Animal Health
|
Dalan Animal Health is a vaccine platform with the potential to combat a variety of devastating bee diseases. The company was founded in 2018 and is headquartered in Athens, Georgia, United States. | $3M / Seed / Nov 19, 2025 | |
Hoofprint Biome
|
Hoofprint Biome is a developer of probiotics that improve the sustainability of ruminant livestock production. Its probiotics and natural enzymes improve cattle health and digestive care by eliminating methane and enabling the livestock industry to catalyze the symbiotic agriculture movement with microbiome engineering. | $15M / Series A / Apr 29, 2025 | |
AdipoPharma
|
AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | Nov 11, 2024 | |
|
AdipoPharma
|
AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M / Series A / Nov 11, 2024 | |
Aralez Bio
|
Aralez Bio uses engineered enzymes to make valuable products in a sustainable way.The company has invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Its proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, withwater as the only byproduct | $12M / Series A / Oct 29, 2024 | |
Liminal
|
Liminal operates as a battery manufacturing intelligence provider that utilizes data and analytics. Its mission is to make electric vehicles the default option for any driver. The company was founded in 2015 and is headquartered in Emeryville, California. | $10M / Venture - Series Unknown / Oct 15, 2024 | |
VenoStent
|
VenoStent is a clinical-stage tissue engineering company that’s developed tunable, bioabsorbable smart polymer wraps in order to fundamentally transform the 5 million vascular surgeries performed each year. | $4M / Series A / Jun 27, 2024 | |
Swift Solar
|
Swift Solar is a company focused on developing advanced solar technology. The company's core innovation is perovskite solar cells, designed to be more efficient and affordable than traditional solar panels. Swift Solar emphasizes domestic manufacturing and abundant raw materials to ensure scalability. | $27M / Series A / Jun 12, 2024 | |
| See all 120 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Good Growth Capital invest in?
Good Growth Capital invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 120 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Good Growth Capital's check size?
Good Growth Capital typically joins rounds of $505k–$9M at Seed, $4.2M–$20M at Series A and $25k–$300k at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Good Growth Capital participates in.
How do I contact Good Growth Capital?
Public channels for Good Growth Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Good Growth Capital?
The team at Good Growth Capital includes Amy Salzhauer (Founder and Managing Partner), Carolyne LaSala (Partner and Managing Partner) and DAVID MENDEZ (Managing Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
